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Background: Acute myeloid leukemia (AML) is a biologically and clinically heterogeneous cancer of the bone
marrow that is characterized by the rapid growth of abnormal myeloid cells.
Methods: We performed a mutational analysis to identify AML somatic mutations using the whole-exome
sequencing data of 36 tumor-normal sample pairs from Korean patients with de novo AML. We explored the
functional impact of the genes identified in the mutational analyses through an integrated Gene Ontology (GO)
and pathway analysis.
Results: A total of 11 genes, including NEFH (p = 6.27 × 10−13 and q = 1.18 × 10−8) and TMPRSS13 (p = 1.40 × 10−10
and q = 1.32 × 10−6), also demonstrated q values less than 0.1 in 36 Korean AML patients. Five out of the 11 novel
genes have previously been reported to be associated with other cancers. Two gene mutations, CEBPA (p = 5.22 ×
10−5) and ATXN3 (p = 9.75 × 10−4), showed statistical significance exclusively in the M2 and M3 subtypes of the
French-American-British classifications, respectively. A total of 501 genes harbored 478 missense, 22 nonsense, 93
frameshift indels, and/or three stop codon deletions and these gene mutations significantly enriched GO terms for
signal transduction (GO:0007165, p = 1.77 × 10−3), plasma membrane (GO:0005886, p = 3.07 × 10−4), and scaffold
protein binding (GO:0097110, p = 8.65 × 10−4). The mitogen-activated protein kinase (hsa04010, 7.67 × 10−4) was the
most enriched Kyoto Encyclopedia of Genes and Genomes pathway.
Conclusions: Morphological AML subtypes may in part reflect subtype specific patterns of genomic alterations.
Following validation, future studies to evaluate the usefulness of these genes in genetic testing for the early
diagnosis and prognostic prediction of AML patients would be worthwhile.
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Acute myeloid leukemia (AML) is a highly malignant
cancer of the bone marrow that is characterized by the
rapid growth of abnormal myeloid cells. In 2012,
leukemia accounted for 2.5% and 3.2% of all new cancer
cases and deaths worldwide, respectively [1]. The inci-
dence rate of leukemia increased from 4.7 to 5 cases per
10,000 Koreans from 1999–2010 [2]. AML cytogenetic* Correspondence: jwpark@hallym.ac.kr
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information for AML patients. However, approximately
50% of AML patients have a normal karyotype (NK-
AML). Although Schlenck et al. showed that the com-
bination of the mutations in FLT and NPM1 or CCAAT/
enhancer binding protein (C/EBP), alpha (CEBPA) could
be used to predict NK-AML prognosis, most patients
did not have this mutation set [3]. This finding suggests
that AML is a highly heterogeneous disease and that a
large number of causal mutations have not yet been un-
covered [4]. Two systems, the French-American-British
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classify AML into subtypes. To compare our results with
the previous studies, we used the FAB system, the most
commonly used classification in previous sequencing
studies for AML, including The Cancer Genome Atlas
(TCGA) whole genome sequencing (WGS) [5, 6]. AML
is classified into eight subtypes (M0 through M7) accord-
ing to the FAB classification based on its morphological
features: early forms in white blood cells (M0-M5), red
blood cells (M6), and platelets (M7) [3].
Next-generation sequencing technologies have extended
AML genetic studies to a genome-wide scope at a single-
base resolution. Ley et al. (2008) performed the first AML
WGS study on one Caucasian woman with the cytogeneti-
cally normal AML subtype M1 and reported non-
synonymous single nucleotide variants (nsSNVs) in eight
genes (i.e., CDH24, PCLKC, GPR123, EBI2, PTPRT,
KNDC1, SLC15A1, and GRINL1B) and insertions in the
coding regions of the FLT3 and NPM1 genes [7]. Mardis
and his colleagues reported that 16% of 80 NK-AML
patients had a somatic point mutation in the IDH1 gene
[8]. According to a later report by Ley et al. (2010),
approximately 22% of 281 AML patients had DNMT3A
mutations that were newly discovered using targeted
sequencing [9]. In a Chinese study using targeted exome
sequencing, the patients with the DNMT3A Arg882 muta-
tion showed poor prognosis among AML-M5 individuals
[10]. A WGS study with eight Caucasian AML patients
showed clonal evolution patterns and mutations associ-
ated with relapsed AML in the genes WAC, SMC3, DIS3,
DDX41, and DAXX [11]. Recently, TCGA analyzed 50 and
150 patients with de novo AML using WGS and whole-
exome sequencing (WES), respectively. They found 23
significantly mutated genes and 237 gene mutations that
recurred in at least two patients, which were grouped into
nine categories according to their biological functions [6].
AML is a clinically and genetically heterogeneous
disease, hence discovering subtype-specific mutations
may provide additional prognostic information for AML
patients. In this study, we aimed to replicate previous
findings in the European studies and to characterize the
landscape of somatic mutations present in Korean acute
myeloid leukemia. We also performed a stratified analysis
for FAB M2- and M3-subtypes to investigate if certain
mutations have subtype-specific effects. We subsequently
evaluated the functional properties of the significantly
mutated genes using an integrated systems analysis of
Gene Ontology (GO) and biological pathways.
Methods
Patients and samples
We included 36 Korean patients with de novo AML who
visited the Division of Hematology and Medical Oncology,
Seoul National University Hospital, from 1995 to 2013who had not received a bone marrow transplant prior to
sampling. All subjects provided matched tumor-normal
sample pairs that passed a DNA quality control (QC) test.
The Institutional Review Board for Human Research at
Seoul National University approved the study protocol
(IRB number 1201-099-396), and all participants signed
informed consent forms for WES. A clinician conducted a
retrospective medical record review to obtain clinical data
including disease status and blood chemistry. An approxi-
mately 10-mL bone marrow sample was aspirated from
each participant by a clinician in an aseptic environment,
and genomic DNA was isolated using the QIAamp DNA
Blood Maxi Kit following the manufacturer’s instructions
(Qiagen, Inc., Valencia, CA, USA). A 2-ml whole-saliva
sample was obtained from the same individuals for the
matched normal samples, and the genomic DNA was
extracted using the Oragen DNA Self-Collection kit
(DNA Genotek, Inc., Ontario, Canada).
Whole-exome sequencing
We captured the target DNA sample using the Agilent
SureSelect Human All Exon 50 Mb Kit (Agilent
Technologies Inc., Santa Clara, CA, USA). The entire
exome regions for both the tumor and normal sam-
ples from 36 AML patients were sequenced using the
HiSeq 2000 platform with a 100 bp paired-end read
protocol (Illumina, Inc. San Diego, CA, USA). Each the
tumor and the normal sample were sequenced to an aver-
age read depth of 76X. The fastq quality score and read
length cutoff determined by the NGS QC-toolkit were set
to 20 and 70, respectively [12]. We aligned the filtered
reads to the reference assembly of human_g1k_v37 fasta
using BWA-0.7.5 [13] and called somatic SNVs using
MuTect v1.1.4 according to the Catalogue of Somatic
Mutations in Cancer (COSMIC) v68 database [14].
We used Varscan v2.3.6 to call short indels [15]. We
obtained translational effect of variant allele, protein
change information, mutation reports in Catalog of
Somatic Mutations in Cancer, and predictions of
coding non-synonymous variants on protein function
using the Oncotator web application [16]. Preliminary re-
ports using six of 36 samples have been previously
published elsewhere (Additional file 1: Table S1) [17–19].
Statistical analysis
We performed a mutation significance test using
MutSigCV v1.4 with a significance threshold of a p
value less than 0.05. The p value was calculated with
the chi-square test to determine whether the observed
mutations in a gene significantly exceeded the expected
frequency of random background mutations. We add-
itionally considered a q value less than 0.1, which was an
analogue of the p value calculated based on the
Benjamini-Hochberg false discovery rate (FDR) [20]. To
Table 1 Characteristics of the 36 acute myeloid leukemia patients
Variables AML (n = 36)
Age, mean (SE) 46.43 (3.09)
Male (%) 22 (61.11)
Absolute neutrophil count × 103/mm3, mean (SE) 1.99 (0.92)
Bone marrow blast (%), mean (SE) 60.93 (4.59)
White blood cell count × 103/mm3, Mean (SE) 25.72 (4.99)
Platelet count × 103/mm3, Mean (SE) 73.34 (13.03)








Abbreviation: AML acute myeloid leukemia, SE standard error
aAML is classified into five subtypes (M1 through M5) according to the French-
American-British (FAB) classification
bOthers are comprised of myelodysplastic syndrome (n = 3) or whose subtype
information was not available (n = 1)
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test individually in each of the subgroups as follows: M2-
AML, acute myeloblastic leukemia with maturation, and
M3-AML, acute promyelocytic leukemia. We screened for
mutations that recurred in more than two patients with a
p value less than 0.05 in any patient group. We catego-
rized a mutant gene as a subtype-specific gene if the statis-
tical significance of any one subgroup (i.e., M2 or M3)
represented exclusively the significance of the total
patient group. Finally, we systematically searched the
PubMed database (www.ncbi.nlm.nih.gov/pubmed) to
review previous studies on the relevance of the genes
with p values less than 0.05 and q values less than
0.1 for AML and/or other cancers.
Gene set enrichment analysis and pathway analysis
To investigate the biological relevance of the mutations,
we performed a GO enrichment analysis with the Data-
base for Annotation, Visualization, and Integrated Dis-
covery (DAVID 6.8 beta) [21]. We categorized the
function of these genes into three classes: ‘biological
process’, ‘cellular components’, and ‘molecular function’.
We also used the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database (http://www.genome.jp/
kegg/pathway.html) to identify pathways for the genes
that were frequently mutated in AML cells [22].
Results
The mean age of the 36 AML patients was approxi-
mately 46 years. The mean percentage of blasts in the
bone marrow (60.93%) in patients in this study was
approximately 12-fold higher than the level in patients
undergoing complete remission. Overall, the abnormally
high WBC count and low platelet count observed in the
study subjects represent typical characteristics of AML
patients. A total of 32 patients were grouped into five
AML subtypes as follows: M1 (n = 43), M2 (n = 11), M3
(n = 12), M4 (n = 3), and M5 (n = 3). However, four
patients were not placed into any of the AML subgroups
(Table 1). Details of the 36 AML patients including sex,
age, FAB subtype, and cytogenetic abnormalities were
shown in Additional file 1: Table S1. Ten of 11 patients
with the acute promyelocytic leukemia (APL)-specific
chromosomal translocations t(15;17) (q22;q21) were
classified into the FAB subtype M3. Eight of 12 AML
patients with normal karyotype fell into the M2 subtype.
Mutation detection
We identified a total of 4,954 intragenic somatic muta-
tions and 43 genes passed a mutation significance p value
threshold 0.01 (data not shown). Among them, 11 genes
demonstrated q values less than 0.1 in 36 AML patients
(Table 2). The most significantly mutated gene in AML
cells was the heavy polypeptide gene (NEFH, p = 6.27 ×10−13, q = 1.18 × 10−8). Frameshift indels potentially lead
to the disease since they alter protein amino acid
sequences which were found in olfactory receptor family 2
subfamily T member 35 (OR2T35) and proprotein conver-
tase subtilisin/kexin type 5 (PCSK5). Missense SNVs were
found in transmembrane protease, serine 13 gene
(TMPRSS13) in six samples, keratin associated protein 4–
5 (KRTAP4-5) in one sample, and G protein regulated in-
ducer of neurite outgrowth 1(GPRIN1) in one sample
(Table 2 and Additional file 1: Table S2).
Subtype-specific somatic mutations
We identified three significantly mutated genes with a p-
value of less than 0.01 for each M2 and M3 group.
Among them, we identified two genes, CEBPA (19q13.1,
p = 5.22 × 10−5) and E1A binding protein p400 (EP400,
12q24.33, p = 4.45 × 10−4), that showed statistical signifi-
cance exclusively in the M2 subtype, as well as one gene,
ataxin 3 (ATXN3, p = 9.75 × 10−4) that was exclusive for
the M3 subtype. In other words, these mutations were
found to be more frequent in either M2 or M3 subgroup
cases than in the total cohort of 36 AML patients
(Table 2). Although only eight genes identified in all
cases after Bonferroni correction for multiple testing
(with a p value cutoff of 1 × 10−5 for the 4,954 genes
under test), 10 among the 16 genes listed in Table 2
were cancer-relevant genes reported by previous studies.
Especially, early studies revealed an association between
the CEBPA mutations and AML. Figure 1 summarizes
the results of our mutational analysis. The –log10 of the
p value for each mutation (y-axis) was plotted against
Table 2 Genes identified through mutational analysis in AML in the total, M2, and M3 subtype patient groups
Gene Chr Type of variant (patients, n) pa qa Previous studiesb
AML (p < 0.01 and q < 0.10)
NEFH 22 In Frame Ins(6)/Del(4) 6.27 × 10-13c 1.18 × 10−8 RCC [23], ESCC [24]
TMPRSS13 11 In Frame Del(6), Missense(5) 1.40 × 10-10c 1.32 × 10−6
KRTAP4-5 17 In Frame Ins(5), Missense(1) 5.07 × 10-8c 3.19 × 10−4
OR2T35 1 Frame Shift Ins(1)/Del(4) 1.50 × 10-7c 7.09 × 10−4
HAVCR1 5 Intron SNV(1), In Frame Del(5), Silent(1) 3.62 × 10-7c 1.37 × 10−3 Colorectal [25], RCC [26]
IFI27 14 In Frame Ins(3) 6.88 × 10-6c 0.02 Ovarian [27], Breast [28]
PCSK5 9 Intron SNV(1), Frame Shift Del(6), 3′UTR Ins(7)/Del(1) 8.50 × 10-6c 0.02 Lung [29]
GPRIN1 5 Missense(1), In Frame Del(5) 8.88 × 10-6c 0.02
MRPL18 6 In Frame Del(3) 2.09 × 10−5 0.04
ARSD X Intron Ins(2)/Del(2), In Frame Del(4) 2.93 × 10−5 0.05 CLL [30]
MAML3 4 In Frame Ins(2)/Del(4), Silent(3), Intron Del(1) 3.33 × 10−5 0.05
AML-M2 (p < 0.01)
CEBPA 19 In Frame Ins(3) 5.22 × 10−5 0.49 HCC [31], AML [32]
EP400 12 Intron Del(1), In Frame Ins(4)/Del(1) 3.45 × 10−4 1 RCC [33], Colorectal [34]
AML-M3 (p < 0.01)
ATXN3 14 In Frame Ins(2), Intron Ins(1) 9.75 × 10−4 1 Lung [35]
Abbreviation: AML acute myeloid leukemia, B-CLL B-cell chronic lymphocytic leukemia, Breast breast cancer, Colorectal colorectal cancer, CLL chronic lymphocytic
leukemia, Chr chromosome, Del deletion, ESCC esophageal squamous cell carcinoma, HCC hepatocellular carcinoma, Ins insertion, Lung lung cancer, MDS
myelodysplastic syndrome, NMSC non-melanoma skin cancer, Ovarian ovarian cancer, RCC renal cell carcinoma, SNV single nucleotide variant
ap and q values were obtained from mutational analysis
bCancers reported by previous studies to have associations with the gene mutations
cThe genes still being significant after Bonferroni correction
Fig. 1 Three genes demonstrating AML subtype specificity (p < 0.01). The symbols, circle (○), triangle (△), and cross (+) denote the significance
levels of each gene estimated in the total, M2- and M3-subtype groups, respectively. The labeled genes demonstrate that their mutational
significance levels are higher in a subtype group than in the total group
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ally, the three subtype-specific mutant genes with a
p value of less than 0.01were labelled in the plot.
Pathways and biological processes
We identified total of 501 genes harbored 478 missense,
22 nonsense, 93 frameshift indels, and/or three stop
codon deletions. We performed GO and KEGG pathway
enrichment analyses with the input consisted of the 501
genes. The GO analysis demonstrated that 43 mutated
genes could contribute to AML tumorigenesis through
the biological processes such as signal transduction (p =
1.77 × 10−3, Fold Enrichment = 1.63). In terms of cellular
components, the plasma membrane showed the most
significant alteration (p = 3.07 × 10−4, Fold Enrichment =
1.32). Scaffold protein binding was the most significantly
altered molecular function (p = 8.65 × 10−4, Fold Enrich-
ment = 6.18). To investigate the pathway-level relation-
ship of the mutated genes, we performed a pathway
analysis in the KEGG database (Additional file 1: Table S3).
Mitogen-activated protein kinase signaling (p = 7.67 × 10−4,
Fold Enrichment = 2.50) and long-term potentiation (p =
2.40 × 10−3, Fold Enrichment = 4.28) pathways were signifi-
cantly altered in AML.
Discussion
A total of 11 genes were significantly mutated in 36
AML patients (p < 0.01 and q < 0.1). Specifically, NEFH,
hepatitis A virus cellular receptor 1 (HAVCR1, 5q33.2),
interferon, alpha-inducible protein 27 (IFI27, 14q32),
PCSK5, and the arylsulfatase D gene (ARSD, Xp22.3)
have been implicated in a variety of cancers. For in-
stance, the variants of NEFH gene, a tumor suppressor,
were suggested as prognostic markers for renal cell
carcinoma (RCC) and contributed to susceptibility of
esophageal squamous cell and hepatocellular carcinomas
[24, 36]. While overexpression of this gene interrupts
the development of cell structure and function in normal
cells [37], loss-of-function mutations in this gene acti-
vate the Akt/β-catenin pathway and cause increased
glycolysis and result in mitochondrial dysfunction in
cancer cells [24]. The transmembrane protease, serine
13 gene (TMPRSS13, 11q23), a splice variant of mosaic
serine protease large form (MSPL), encodes a family of
the type II transmembrane serine proteases which plays
critical roles in maintaining homeostasis, infection, and
tumorigenesis [38, 39]. The HAVCR1 gene is a bio-
marker for diagnosing renal cell, ovarian, and colorectal
carcinoma [25, 40]. Especially, elevated expression of this
gene prevents cancer cell invasion and adhesion in colo-
rectal cancer cells [25]. IFI27, the most highly up-
regulated gene in human whole blood, is related with
immune response through activation of T lymphocytes
and dendritic cells [41]. Furthermore, this gene inducesthe interferon-alpha and stimulates myeloid dendritic
cells [42]. The proprotein convertases (PCs) play im-
portant roles in development and metastasis of mul-
tiple cancers. The PCSK5 gene (also known as PC5
or PC6) has been reported to be systematically down-
regulated in intestinal tumors of the knockout mouse
model and human [43].
The protein encoded by the ARSD gene located on X
chromosome is a member of the sulfatase family, which
is an essential element for skeletal and cartilage growth.
The elevated expression of this protein was suggested to
be associated with lipid metabolism such as sphingolipid
and development of chronic lymphocytic leukemia [30].
A cluster of Mastermind-like (MAML) genes, including
MAML1, MAML2, and MAML3, encodes transcriptional
co-activators for various signal pathways such as Notch
signaling and tumor suppressor pathway activated in
multiple cancers [44]. Specifically, the MAML3 gene
regulates the retinoic acid gene, which inhibits growth of
human tumor cells [45]. We identified four novel genes,
KRTAP4-5, OR2T35, GPRIN1, and MRPL18, of unknown
function in tumor progression and metastasis.
The genes mutated exclusively in the patients with the
AML subtypes M2 and M3 have been reported more
frequently in previous studies to have an association
with AML and/or other types of cancers than the genes
identified in the total AML patient group. For instance,
previous NGS studies for AML evaluated the prognostic
impact of the gene CEBPA in AML patients [6, 32]. This
gene had the lowest p value in the AML M2 group in
the current study. The high proportion of M2-patients
in the study subjects may have affected the results of
previous studies. The E1A binding protein p400 (EP400,
12q24.33) was reported to be associated with cancers
such as RCC and colorectal cancer. All three genes
specific to the M3 subtype (ATXN3, thymine-DNA gly-
cosylase (TDG, 12q24.1), and HCLS) also showed
possible associations with cancer risks, such as B-cell
chronic lymphocytic leukemia (B-CLL).
Gene set enrichment analysis showed that MAPK sig-
naling pathway was significantly enriched in the 36
Korean AMLs. MAPKs play important role in convert-
ing extracellular stimuli into cellular responses and are
often altered in cancers [46]. The genomic region,
Chromosome 11:117789342–117789345, harbor five
missense mutations leading to protein changes, p.A77G
and p.Q78R, of transmembrane serine proteases that is
known to function in tumorigenesis [39]. We addition-
ally investigated the clinical features of patients who
share the same recurrent mutations, including age, abso-
lute neutrophil count, bone marrow blast percentage,
white blood cell count, platelet count, and overall sur-
vival time, however there were no specific clinical fea-
tures observed among them.
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In this study, we replicated multiple gene mutations
reported by previous European studies in Korean pa-
tients. We also discovered novel genes significantly
mutated in AMLs and some mutated genes that showed
subtype-specific patterns of mutations. The effects of
novel genes and subtype-specific somatic mutations in
AML warrant further validation in larger cohorts.
Following validation, it would be worthwhile in future
studies to evaluate the usefulness of these genes in
genetic testing for the early diagnosis and prediction of
the prognosis of AML patients.
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Abbreviations
AML: Acute myeloid leukemia; ANK-AML: AML with an abnormal karyotype;
APL: Acute promyelocytic leukemia; CPH: Cox proportional hazards
regression; FAB: French-American-British classification; FDR: False discovery
rate; GO: Gene ontology; IGV: Integrative genomics viewer; INO80: INO80
complex subunit; JMML: Juvenile myelomonocytic leukemia; LR: Logistic
regression; MAPK: Mitogen-activated protein kinase; NGS: Next-generation
sequencing technologies; NK-AML: AML with a normal karyotype;
nsSNVs: Non-synonymous single nucleotide variants; OR: Odds ratio;
TCGA: The Cancer Genome Atlas Research Network; WBC: White blood cells;
WES: Whole-exome sequencing; WGS: Whole genome sequencing
Acknowledgments
The authors thank all participants who donated samples and the staff
members who were involved in this research. We especially acknowledge
the contributions of Young Ki Lee (Syntekabio, Inc., Republic of Korea) who
worked on NGS data generation, and Eun Pyo Hong (Hallym University
College of Medicine, Republic of Korea) who contributed to the evaluation
of the functional importance of the gene mutations.
Funding
This research was supported by grant of the Korea Health Industry
Development Institute (KHIDI) of the Ministry of Health & Welfare
(HI14C0072) and the National Research Foundation (NRF) of the Ministry of
Education (2014R1A1A3053168), Republic of Korea.
Availability of data and materials
The data that support the findings are available in this published article and its
supplementary information files; and the datasets analysed during the current
study are available from the corresponding author on reasonable request.
Authors’ contributions
PJW have made substantial contribution to design of the work,
interpretation of data, writing the manuscript and revising it critically for
important intellectual content. HSG and KJK participated in the analysis and
interpretation of data and drafting the manuscript. KY and YS participated in
the study design, data acquisition, and clinical data evaluation. KHL
contributed to the design of the study. JJS oversaw generation of
sequencing data and participated in writing of the manuscript. All
co-authors approved the final version of the manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.Ethics approval and consent to participate
The Institutional Review Board for Human Research at Seoul National
University approved the study protocol (IRB number 1201-099-396), and all
participants signed informed consent forms.
Author details
1Department of Medical Genetics, College of Medicine, Hallym University, 1
Hallymdaehak-gil, Chuncheon, Gangwon-do 24252, Republic of Korea. 2Wide
River Institute of Immunology, Seoul National University, Hongcheon,
Republic of Korea. 3Department of Internal Medicine, Seoul National
University Hospital, Seoul, Republic of Korea. 4Omics Core Lab., National
Cancer Center, Goyang, Republic of Korea. 5The Catholic University, Seoul,
Republic of Korea. 6Syntekabio Inc., Seoul, Republic of Korea. 7Department of
Biochemistry, School of Medicine, Ewha Womans University, Seoul, Republic
of Korea.
Received: 24 January 2016 Accepted: 15 February 2017
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.
2. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in
Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res
Treat. 2013;45:1–14.
3. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al.
Mutations and treatment outcome in cytogenetically normal acute myeloid
leukemia. N Engl J Med. 2008;358:1909–18.
4. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al.
Prognostic relevance of integrated genetic profiling in acute myeloid
leukemia. N Engl J Med. 2012;366:1079–89.
5. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular
prognostic markers for adult acute myeloid leukemia with normal
cytogenetics. J Hematol Oncol. 2009;2:23.
6. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes
of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
7. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA
sequencing of a cytogenetically normal acute myeloid leukaemia genome.
Nature. 2008;456:66–72.
8. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al.
Recurring mutations found by sequencing an acute myeloid leukemia
genome. N Engl J Med. 2009;361:1058–66.
9. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al.
DNMT3A mutations in acute myeloid leukemia. N Engl J Med.
2010;363:2424–33.
10. Yan X-J, Xu J, Gu Z-H, Pan CM, Lu G, Shen Y, et al. Exome sequencing
identifies somatic mutations of DNA methyltransferase gene DNMT3A in
acute monocytic leukemia. Nat Genet. 2011;43:309–15.
11. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal
evolution in relapsed acute myeloid leukaemia revealed by whole-genome
sequencing. Nature. 2012;481:506–10.
12. Patel RK, Jain M. NGS QC Toolkit: a toolkit for quality control of next
generation sequencing data. PLoS One. 2012;7:e30619.
13. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics. 2010;26:589–95.
14. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al.
Sensitive detection of somatic point mutations in impure and
heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.
15. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan
2: somatic mutation and copy number alteration discovery in cancer by
exome sequencing. Genome Res. 2012;22:568–76.
16. Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, et al.
Oncotator: cancer variant annotation tool. Hum Mutat. 2015;36:E2423–2429.
17. Park S, Koh Y, Yoon SS. Effects of somatic mutations are associated with
SNP in the progression of individual acute myeloid leukemia patient: the
two-hit theory explains inherited predisposition to pathogenesis. Genomics
Inform. 2013;11:34–7.
18. Lee KH, Lim JH, Kim JH. Annotation of genes having candidate somatic
mutations in acute myeloid leukemia with whole-exome sequencing using
concept lattice analysis. Genomics Inform. 2013;11:38–45.
Heo et al. BMC Medical Genetics  (2017) 18:23 Page 7 of 719. Heo SG, Hong EP, Park JW. Genetic risk prediction for normal-karyotype
acute myeloid leukemia using whole-exome sequencing. Genomics Inform.
2013;11:46–51.
20. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A,
et al. Mutational heterogeneity in cancer and the search for new cancer-
associated genes. Nature. 2013;499:214–8.
21. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nature Protoc.
2009;4:44–57.
22. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data,
information, knowledge and principle: back to metabolism in KEGG. Nucleic
Acids Res. 2014;42:D199–205.
23. Dubrowinskaja N, Gebauer K, Peters I, Hennenlotter J, Abbas M, Scherer R,
et al. Neurofilament Heavy polypeptide CpG island methylation associates
with prognosis of renal cell carcinoma and prediction of antivascular
endothelial growth factor therapy response. Cancer Med. 2014;3:300–9.
24. Kim MS, Chang X, LeBron C, Nagpal JK, Lee J, Huang Y, et al. Neurofilament
heavy polypeptide regulates the Akt-beta-catenin pathway in human
esophageal squamous cell carcinoma. PLoS One. 2010;5:e9003.
25. Wang Y, Martin TA, Jiang WG. HAVcR-1 expression in human colorectal
cancer and its effects on colorectal cancer cells in vitro. Anticancer Res.
2013;33:207–14.
26. Cuadros T, Trilla E, Sarró E, Vilà MR, Vilardell J, et al. HAVCR/KIM-1 activates
the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines
tumor progression and patient outcome. Cancer Res. 2014;74:1416–28.
27. Li S, Xie Y, Zhang W, Gao J, Wang M, Zheng G, et al. Interferon alpha-
inducible protein 27 promotes epithelial-mesenchymal transition and
induces ovarian tumorigenicity and stemness. J Surg Res. 2015;193:255–64.
28. Rasmussen UB, Wolf C, Mattei MG, Chenard MP, Bellocq JP, Chambon P, Rio
MC, Basset P. Identification of a new interferon-alpha-inducible gene (p27)
on human chromosome 14q32 and its expression in breast carcinoma.
Cancer Res. 1993;53:4096–101.
29. Demidyuk IV, Shubin AV, Gasanov EV, Kurinov AM, Demkin VV, Vinogradova
TV, et al. Alterations in gene expression of proprotein convertases in human
lung cancer have a limited number of scenarios. PLoS One. 2013;8:e55752.
30. Trojani A, Di Camillo B, Tedeschi A, Lodola M, Montesano S, Ricci F, et al.
Gene expression profiling identifies ARSD as a new marker of disease
progression and the sphingolipid metabolism as a potential novel
metabolism in chronic lymphocytic leukemia. Cancer Biomark.
2011–2012;11:15–28.
31. Lu GD, Ang YH, Zhou J, Tamilarasi J, Yan B, Lim YC, et al. CCAAT/enhancer
binding protein α predicts poorer prognosis and prevents energy
starvation-induced cell death in hepatocellular carcinoma. Hepatology.
2015;61:965–78.
32. Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, et al.
The role of different genetic subtypes of CEBPA mutated AML. Leukemia.
2014;28:794–803.
33. Macher-Goeppinger S, Bermejo JL, Schirmacher P, Pahernik S, Hohenfellner
M, Roth W. Senescence-associated protein p400 is a prognostic marker in
renal cell carcinoma. Oncol Rep. 2013;30:2245–53.
34. Mattera L, Escaffit F, Pillaire MJ, Selves J, Tyteca S, Hoffmann JS, et al. The
p400/Tip60 ratio is critical for colorectal cancer cell proliferation through
DNA damage response pathways. Oncogene. 2009;28:1506–17.
35. Sacco JJ, Yau TY, Darling S, Patel V, Liu H, Urbé S, et al. The deubiquitylase
Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene.
2014;33:4265–72.
36. Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Powers S,
et al. Genome-wide methylation analysis and epigenetic unmasking identify
tumor suppressor genes in hepatocellular carcinoma. Gastroenterology.
2013;145:1424–35.e1-25.
37. Szebenyi G, Smith GM, Li P, Brady ST. Overexpression of neurofilament H
disrupts normal cell structure and function. J Neurosci Res. 2002;68:185–98.
38. Okumura Y, Takahashi E, Yano M, Ohuchi M, Daidoji T, Nakaya T, et al. Novel
type II transmembrane serine proteases, MSPL and TMPRSS13,
Proteolytically activate membrane fusion activity of the hemagglutinin of
highly pathogenic avian influenza viruses and induce their multicycle
replication. J Virol. 2010;84:5089–96.
39. Hashimoto T, Kato M, Shimomura T, Kitamura N. TMPRSS13, a type II
transmembrane serine protease, is inhibited by hepatocyte growth factor
activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS
J. 2010;277:4888–900.40. Lin F, Zhang PL, Yang XJ, Shi J, Blasick T, Han WK, et al. Human kidney injury
molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing
renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol.
2007;31:371–81.
41. Hsiao C-P, Araneta M, Wang XM, Saligan LN. The association of IFI27 expression
and fatigue intensification during localized radiation therapy: implication of a
para-inflammatory bystander response. Int J Mol Sci. 2013;14:16943–57.
42. Naing A, Reuben JM, Camacho LH, Gao H, Lee B-N, Cohen EN, et al. Phase I
Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine
Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with
Solid Tumors. J Cancer. 2011;2:81–9.
43. Sun X, Essalmani R, Seidah NG, Prat A. The proprotein convertase PC5/6 is
protective against intestinal tumorigenesis: in vivo mouse model. Mol
Cancer. 2009;8:73.
44. McElhinny AS, Li J-L, Wu L. Mastermind-like transcriptional co-activators:
emerging roles in regulating cross talk among multiple signaling pathways.
Oncogene. 2008;27:5138–47.
45. Heynen GJJE, Nevedomskaya E, Palit S, Jagalur Basheer N, Lieftink C,
Schlicker A, et al. Mastermind-Like 3 Controls Proliferation and
Differentiation in Neuroblastoma. Mol Cancer Res MCR. 2016;14:411–22.
46. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways
in cancer development. Nat Rev Cancer. 2009;9:537–49.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
